Targeted and novel therapy in advanced gastric cancer

The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transi...

Descripción completa

Detalles Bibliográficos
Autores principales: Selim, Julie H., Shaheen, Shagufta, Sheu, Wei-Chun, Hsueh, Chung-Tsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788003/
https://www.ncbi.nlm.nih.gov/pubmed/31632839
http://dx.doi.org/10.1186/s40164-019-0149-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788003/
https://www.ncbi.nlm.nih.gov/pubmed/31632839
http://dx.doi.org/10.1186/s40164-019-0149-6

Ejemplares similares